Publications by authors named "Emanuela Merla"

Claim this Profile
I
Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide.
Jacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, Samia Harbi, Francesca Patriarca, Emanuela Merla

Bone Marrow Transplant· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience.
Massimo Martino, Annalisa Pitino, Mercedes Gori, Benedetto Bruno, Alessandra Crescimanno, Emanuela Merla

Front Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy.
Jacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, Angelo Michele Carella, Massimo Martino, Emanuela Merla

Blood Adv· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms' tumor 1 expression.
Giovanni Rossi, Angelo Michele Carella, Maria Marta Minervini, Francesco di Nardo, Chiara de Waure, Emanuela Merla

Leuk Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Pier Luigi Zinzani, Cinzia Pellegrini, Emanuela Merla, Filippo Ballerini, Alberto Fabbri

Hematol Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Giovanni Rossi, Angelo Michele Carella, Maria Marta Minervini, Lucia Savino, Andrea Fontana, Emanuela Merla

Leuk Lymphoma· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia.
Nicola Cascavilla, Giovanni D'Arena, Michele Mario Greco, Lorella Melillo, Emanuela Merla

Br J Haematol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo, Tommasina Guglielmelli, Renato Zambello, Emanuela Merla

Leuk Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Antonio Palumbo, Sara Bringhen, Tommaso Caravita, Emanuela Merla, Vincenzo Capparella

Lancet· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis